Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.
Ramona Dadu, MD, endocrinologist, MD Anderson Cancer Center, discusses the benefits of using immunotherapies in thyroid cancer and some of the potential drawbacks that coincide with the treatments. Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More